Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint

Lipocine said LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17 total score compared to placebo at hour 60 in the overall study population, and the primary endpoint was not met.